Lung Cancer (Systemic Therapy)
Summary Recommendations
Pathological reporting and molecular subtyping
First-line treatment options for epidermal growth factor receptor (EGFR) sensitising mutation-positive advanced Non- Small Cell Lung Cancer (NSCLC)
First-line treatment options for advanced Non- Small Cell Lung Cancer (NSCLC) harbouring anaplastic lymphoma kinase (ALK) gene rearrangement
First-line chemotherapeutic options for advanced Non- Small Cell Lung Cancer (NSCLC) with no driver mutation
Role of maintenance chemotherapy
Second-line chemotherapeutic options
Subsequent lines of treatment options
References
All categories
- Bladder Cancer
- Breast Cancer (Trastuzumab Use)
- Breast Cancer (Bisphosphonate Use)
- Colorectal Cancer (Adjuvant)
- Colorectal Cancer (Palliative)
- Endometrial Cancer
- Glioma
- Hereditary Cancer
- Lung Cancer (Adjuvant Chemotherapy)
- Lung Cancer (Systemic Therapy)
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cell Carcinoma
- Sarcoma (Extremity STS and Osteosarcoma)
- Sarcoma (Retroperitoneal STS)